May 15, 2014 11:00 UTC

BioLineRx to Report First Quarter 2014 Results on May 20, 2014

Management to hold a conference call at 10:00 a.m. EDT

JERUSALEM--(BUSINESS WIRE)-- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it will release its unaudited financial results for the quarter ended March 31, 2014 on Tuesday, May 20, 2014, before the U.S. markets open.

The Company will host a conference call on Tuesday, May 20 at 10:00 a.m. EDT featuring remarks by Kinneret Savitsky, Ph.D., Chief Executive Officer of BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of BioLineRx. A presentation will be provided on BioLineRx’s website, to accompany management’s remarks on the conference call. The conference call will be available via webcast and can be accessed through the Investor Relations section of BioLineRx’s website, www.biolinerx.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. To dial into the conference call, please dial 1-888-860-9642 from the U.S. or +972-3-918-0691 internationally.

A replay of the conference call will be available approximately two hours after completion of the live conference call at www.biolinerx.com. A dial-in replay of the call will be available until May 23, 2014; please dial 1-888-276-1485 from the U.S. or +972-3-9255945 internationally.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a pivotal CE-Mark registration trial; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is in the midst of a Phase 1/2 study.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases, and events. BioLineRx’s IR app is available on the iTunes App Store as well as the Google Play Store.

Contacts

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
+1-212-375-2664
jdrumm@tiberend.com
or
Andrew Mielach
+1-212-375-2694
amielach@tiberend.com
or
BioLineRx Ltd.
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipihai5@gmail.com


Source: BioLineRx Ltd.